<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Aztreonam (oral inhalation): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Aztreonam (oral inhalation): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Aztreonam (oral inhalation): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="104067" href="/d/html/104067.html" rel="external">see "Aztreonam (oral inhalation): Drug information"</a> and <a class="drug drug_patient" data-topicid="104070" href="/d/html/104070.html" rel="external">see "Aztreonam (oral inhalation): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F29768794"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cayston</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872000"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cayston</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F29837358"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Miscellaneous</span></li></ul></div>
<div class="block dop drugH1Div" id="F29768851"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="df85d498-37b3-4d24-95e1-d4a9ea8cb8c0">Cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis </b>
<i>
<b>(Pseudomonas aeruginosa)</b></i>
<b>:</b> Inhalation (nebulizer): Infants ≥3 months, Children, and Adolescents (limited data available in ages &lt;7 years): 75 mg via nebulization 3 times daily (at least 4 hours apart) for 28 days; administer in repeated cycles of 28 days on drug, followed by 28 days off drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27009033','lexi-content-ref-25091537','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27009033','lexi-content-ref-25091537','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51073354"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥7 years and Adolescents: No adjustment required with any level of renal impairment due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F51073355"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.</p></div>
<div class="block doa drugH1Div" id="F29768852"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="104067" href="/d/html/104067.html" rel="external">see "Aztreonam (oral inhalation): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="df85d498-37b3-4d24-95e1-d4a9ea8cb8c0">Cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Cystic fibrosis:</b> Inhalation (nebulizer): 75 mg 3 times daily (at least 4 hours apart) for 28 days; administer in repeated cycles of 28 days on drug, followed by 28 days off drug. <b>Note:</b> Pretreatment with a bronchodilator is recommended.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990261"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50987430"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;">
<i>US labeling:</i> There are no dosage adjustments provided in the manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>No dosage adjustment is necessary; minimal systemic absorption following inhalation.</p></div>
<div class="block adr drugH1Div" id="F29768818"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Pharyngolaryngeal pain (12%) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Respiratory: Cough (54%), nasal congestion (16%), wheezing (16%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Miscellaneous: Fever (13%; more common in children)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardiovascular: Chest discomfort (8%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dermatologic: Skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gastrointestinal: Abdominal pain (7%), vomiting (6%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Respiratory: Bronchospasm (3%; patients experienced ≥15% reduction in FEV<sub>1</sub>) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;1%, postmarketing, and/or case reports: Arthralgia, facial rash, facial swelling, hypersensitivity reaction, joint swelling, pharyngeal edema </p></div>
<div class="block coi drugH1Div" id="F29768815"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to aztreonam or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F29768816"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Beta-lactam allergy: Rare cross-allergenicity to penicillins, cephalosporins, or carbapenems may occur; use with caution in patients with a history of hypersensitivity to beta-lactams.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospasm: May occur following nebulization; administer a bronchodilator prior to treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Compare patient's baseline FEV<sub>1</sub> prior to therapy and the presence of other symptoms when deciding if post-treatment FEV<sub>1</sub> changes (eg, decline) are caused by a pulmonary exacerbation. Reserve use for cystic fibrosis (CF) patients with known <i>Pseudomonas aeruginosa</i>.</p></div>
<div class="block foc drugH1Div" id="F29768870"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Inhalation [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cayston: 75 mg (1 mL) [arginine free]</p></div>
<div class="block geq drugH1Div" id="F29768797"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F29768872"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cayston Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per mL): $171.18</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872001"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cayston: 75 mg (1 ea)</p></div>
<div class="block accres drugH1Div" id="F29768789"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Cayston (aztreonam inhalation solution) is only available through a select group of specialty pharmacies and cannot be obtained through a retail pharmacy. Because Cayston may only be used with the Altera Nebulizer System, it can only be obtained from the following specialty pharmacies; IV Solutions/Maxor; Foundation Care; Pharmaceutical Specialties Inc; TLCRx/ModernHEALTH; and Walgreens Specialty Pharmacy. This network of specialty pharmacies ensures proper access to both the drug and device. To obtain the medication and proper nebulizer, contact the Cayston Access Program at 1-877-7CAYSTON (1-877-722-9786) or at www.cayston.com. In Canada, Cayston is distributed by Innomar Solutions specialty pharmacy; Canadian healthcare providers and patients may obtain additional information at http://cayston.ca/
                  </p></div>
<div class="block admp drugH1Div" id="F52614613"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Inhalation: For inhalation only; not for IM or IV use. Reconstitute immediately prior to use. Administer only using an Altera nebulizer system; dose can be nebulized over 2 to 3 minutes. Administer alone; do not mix with other inhaled nebulizer medications. Administer doses ≥4 hours apart. Administer a bronchodilator before administration of aztreonam (short-acting: 15 minutes to 4 hours before; long-acting: 30 minutes to 12 hours before). For patients on multiple inhaled therapies, administer bronchodilator first, then mucolytic, and lastly, aztreonam.</p></div>
<div class="block adm drugH1Div" id="F29768856"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Administer using only an Altera nebulizer system; <b>administer alone; do not mix with other nebulizer medications</b>. Administer a bronchodilator before administration of aztreonam (short-acting: 15 minutes to 4 hours before; long-acting: 30 minutes to 12 hours before). For patients on multiple inhaled therapies, administer bronchodilator first, then mucolytic, and lastly, aztreonam.</p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;">To administer Cayston, pour reconstituted solution into the handset of the nebulizer system, turn unit on. Place the mouthpiece in the patient’s mouth and encourage to breathe normally through the mouth. Administration time is usually 2 to 3 minutes. Administer doses ≥4 hours apart.</p></div>
<div class="block sts drugH1Div" id="F29768831"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Prior to reconstitution, store at 2°C to 8°C (36°F to 46°F). Once removed from refrigeration, aztreonam and the diluent may be stored at room temperature (up to 25°C [77°F]) for ≤28 days. Protect from light. Use immediately after reconstitution.</p></div>
<div class="block usep drugH1Div" id="F53571276"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Improve respiratory symptoms in cystic fibrosis patients with <i>Pseudomonas aeruginosa</i> in the lungs (FDA approved in ages ≥7 years and adults).</p></div>
<div class="block mst drugH1Div" id="F29768787"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Aztreonam may be confused with azidothymidine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F29768825"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F44575971"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F29768811"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Aztreonam crosses the placenta and reaches the fetal circulation following IV administration; however, peak plasma concentrations following inhalation of aztreonam are significantly less than those observed following aztreonam IV.</p>
<p style="text-indent:0em;margin-top:2em;">Due to its poor systemic absorption, use of aztreonam inhalation is likely acceptable for the management of cystic fibrosis in pregnant patients with <i>Pseudomonas aeruginosa </i>(Kroon 2018; Middleton 2019). When required, use may continue during pregnancy (Middleton 2019).</p></div>
<div class="block mopp drugH1Div" id="F53571277"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">FEV<sub>1</sub>.</p></div>
<div class="block pha drugH1Div" id="F29768835"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs), which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases), while cell wall assembly is arrested. Monobactam structure makes cross-allergenicity with beta-lactams unlikely.</p></div>
<div class="block phk drugH1Div" id="F29768837"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Low systemic absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~77%.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~1 hour (plasma).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Adults: 2.1 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (10% [compared with 60% to 65% for injection] as unchanged drug).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>
</li>
<li>
<div class="reference">
                  Cayston (aztreonam) [prescribing information]. Foster City, CA: Gilead Sciences, Inc; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cayston.2">
<a name="Cayston.2"></a>Cayston (aztreonam) [product monograph]. Mississauga, Ontario, Canada: Gilead Sciences Canada Inc; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29233472">
<a name="29233472"></a>Kroon MAGM, Akkerman-Nijland AM, Rottier BL, Koppelman GH, Akkerman OW, Touw DJ. Drugs during pregnancy and breast feeding in women diagnosed with cystic fibrosis - an update. <i>J Cyst Fibros</i>. 2018;17(1):17-25. doi: 10.1016/j.jcf.2017.11.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-oral-inhalation-pediatric-drug-information/abstract-text/29233472/pubmed" id="29233472" target="_blank">29233472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27009033">
<a name="27009033"></a>Lahiri T, Hempstead SE, Brady C, et al. Clinical practice guidelines from the Cystic Fibrosis Foundation for preschoolers with cystic fibrosis. <i>Pediatrics</i>. 2016;137(4):e20151784.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-oral-inhalation-pediatric-drug-information/abstract-text/27009033/pubmed" id="27009033" target="_blank">27009033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20500046">
<a name="20500046"></a>Le J, Ashley ED, Neuhauser MM, et al. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i>. 2010;30(6):562-584.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-oral-inhalation-pediatric-drug-information/abstract-text/20500046/pubmed" id="20500046" target="_blank">20500046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force statement on the management of reproduction and pregnancy in women with airways diseases [published online November 7, 2019]. <i>Eur Respir J</i>. doi: 10.1183/13993003.01208-2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-oral-inhalation-pediatric-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19420195">
<a name="19420195"></a>Retsch-Bogart GZ, Quittner Al, Gibson RL, et al, “Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis,” <i>Chest</i>, 2009, 135 (5):1223-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-oral-inhalation-pediatric-drug-information/abstract-text/19420195/pubmed" id="19420195" target="_blank">19420195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25091537">
<a name="25091537"></a>Tiddens HA, De Boeck K, Clancy JP, et al. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study. <i>J Cyst Fibros</i>. 2015;14(1):111-119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-oral-inhalation-pediatric-drug-information/abstract-text/25091537/pubmed" id="25091537" target="_blank">25091537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22911974">
<a name="22911974"></a>Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. <i>Pediatr Pulmonol</i>. 2012;47(12):1147-1158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-oral-inhalation-pediatric-drug-information/abstract-text/22911974/pubmed" id="22911974" target="_blank">22911974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23359557">
<a name="23359557"></a>Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive Summary. <i>Pediatr Pulmonol</i>. 2013;48(6):525-537.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/aztreonam-oral-inhalation-pediatric-drug-information/abstract-text/23359557/pubmed" id="23359557" target="_blank">23359557</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 104180 Version 70.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
